ArticleMicrobial cell factories2012
Whole cell biosynthesis of a functional oligosaccharide, 2'-fucosyllactose, using engineered Escherichia coli.
Article in Microbial cell factories, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 123 citations in OpenAlex.
- Prebiotics in animal nutrition: Harnessing agro-industrial waste for improved gut health and performance.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2025Review
- Recent advances in the Design-Build-Test-Learn (DBTL) cycle for systems metabolic engineering of Corynebacterium glutamicum.Journal of microbiology (Seoul, Korea) · 2025Review
- Synbiotic modulation of adult gut microbiome by 2'-fucosyllactose andMicrobiome research reports · 2025Article
- Human Milk Oligosaccharides: Decoding Their Structural Variability, Health Benefits, and the Evolution of Infant Nutrition.Nutrients · 2024Review
- Guide RNA structure design enables combinatorial CRISPRa programs for biosynthetic profiling.Nature communications · 2024Article
- Metabolic Engineering of De Novo Pathway for the Production of 2'-Fucosyllactose in Escherichia coli.Molecular biotechnology · 2023Article
- Human milk oligosaccharide 2'-fucosyllactose promotes melanin degradation via the autophagic AMPK-ULK1 signaling axis.Scientific reports · 2022Article
- Article
- Elucidating Human Milk Oligosaccharide biosynthetic genes through network-based multi-omics integration.Nature communications · 2022Article
- Metabolic engineering strategies of de novo pathway for enhancing 2'-fucosyllactose synthesis in Escherichia coli.Microbial biotechnology · 2022Article
- Synthesis as an Expanding Resource in Human Milk Science.Journal of the American Chemical Society · 2021Review
- Multi-Path Optimization for Efficient Production of 2'-Fucosyllactose in an EngineeredFrontiers in bioengineering and biotechnology · 2020Article
- Prebiotics: tools to manipulate the gut microbiome and metabolome.Journal of industrial microbiology & biotechnology · 2019Review
- Biocatalysis of Fucodian inMarine drugs · 2019Article
- Production of a human milk oligosaccharide 2'-fucosyllactose by metabolically engineered Saccharomyces cerevisiae.Microbial cell factories · 2018Article
- Overcoming the limited availability of human milk oligosaccharides: challenges and opportunities for research and application.Nutrition reviews · 2016Review
- Use of canonical discriminant analysis to study signatures of selection in cattle.Genetics, selection, evolution : GSE · 2016Article
- The sweet branch of metabolic engineering: cherry-picking the low-hanging sugary fruits.Microbial cell factories · 2015Review
- Human Milk Oligosaccharides (HMOS): Structure, Function, and Enzyme-Catalyzed Synthesis.Advances in carbohydrate chemistry and biochemistry · 2015Review
- Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants.Microbiome · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background2'-Fucosyllactose (2-FL) is a functional oligosaccharide present in human milk which protects against the infection of enteric pathogens. Because 2-FL can be synthesized through the enzymatic fucosylation of lactose with guanosine 5'-diphosphate (GDP)-l-fucose by α-1,2-fucosyltransferase (FucT2), an 2-FL producing Escherichia coli can be constructed through overexpressing genes coding for endogenous GDP- l-fucose biosynthetic enzymes and heterologous fucosyltransferase.
resultsThe gene for FucT2 from Helicobacter pylori was introduced to the GDP-l-fucose producing recombinant E. coli BL21 star(DE3) strain. However, only small amount of 2-FL was produced in a batch fermentation because the E. coli BL21star(DE3) strain assimilated lactose instead of converting to 2-FL. As an alternative host, the E. coli JM109(DE3) strain which is incapable of assimilating lactose was chosen as a 2-FL producer. Whole cell biosynthesis of 2-FL from lactose was investigated in a series of batch fermentations using various concentrations of lactose. The results of batch fermentations showed that lactose was slowly assimilated by the engineered E. coli JM109(DE3) strain and 2-FL was synthesized without supplementation of another auxiliary sugar for cell growth. A maximum 2-FL concentration of 1.23 g/l was obtained from a batch fermentation with 14.5 g/l lactose. The experimentally obtained yield (g 2-FL/g lactose) corresponded to 20% of the theoretical maximum yield estimated by the elementary flux mode (EFM) analysis.
conclusionsThe experimental 2-FL yield in this study corresponded to about 20% of the theoretical maximum yield, which suggests further modifications via metabolic engineering of a host strain or optimization of fermentation processes might be carried out for improving 2-FL yield. Improvement of microbial production of 2-FL from lactose by engineered E. coli would increase the feasibility of utilizing 2-FL as a prebiotic in various foods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.